Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 ...
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide, an ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
The VER-01 therapy – a cannabis extract that includes the full range of cannabinoid compounds including low levels of THC – was effective as a treatment for chronic lower back pain in a pair of ...
Many trials exclude certain groups, and do so deliberately—children, for example, or people with physical or learning ...
Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., ...
Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...
A California-based startup has come up with the world’s first injectable CBD product that it claims can help treat an array ...
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Discover why pharmaceutical-grade supplements command premium prices and whether their higher standards of purity, potency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback